ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2020 - 2026)

ARS Pharmaceuticals has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $287.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 12.14% year-over-year to $287.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 16.41% YoY) and the FY2025 annual result came in at $327.7 million, down 6.69% from the prior year.
• Liabilities and Shareholders Equity declined to $287.6 million in Q1 2026 per SPRY's latest filing, from $327.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $372.8 million in Q3 2025 and troughed at $217.6 million in Q3 2024.
• A 5-year average of $283.4 million and a median of $281.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 358.02% in 2022, down 23.12% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $281.4 million in 2022, then fell by 17.14% to $233.2 million in 2023, then soared by 50.59% to $351.2 million in 2024, then slipped by 6.69% to $327.7 million in 2025, then retreated by 12.23% to $287.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $287.6 million, $327.7 million, and $372.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.